Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.44 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | GFER | P55789 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4882024 | 0.80 | KEAP1 (0.42) | KEAP1NFE2L2 | |
| SCHEMBL5044728 | 0.80 | KEAP1 (0.42) | KEAP1NFE2L2 | |
| SCHEMBL30453502 | 0.80 | KEAP1 (0.47) | KEAP1NFE2L2ALDH1A1 | |
| SCHEMBL8235127 | 0.80 | KEAP1 (0.47) | KMT2AKEAP1NFE2L2NPSR1 | |
| SCHEMBL336213 | 0.80 | KEAP1 (0.47) | KEAP1NFE2L2ALDH1A1 | |
| SCHEMBL29260193 | 0.77 | KEAP1 (0.56) | KEAP1NFE2L2 | |
| SCHEMBL13040092 | 0.77 | KEAP1 (0.40) | KMT2AKEAP1NFE2L2 | |
| SCHEMBL9254451 | 0.76 | KMT2A (0.50) | KMT2ANPSR1ALDH1A1GFER | |
| SCHEMBL2796325 | 0.75 | KEAP1 (0.39) | KMT2AKEAP1NFE2L2ALDH1A1GFER | |
| SCHEMBL25354596 | 0.74 | KEAP1 (0.42) | KEAP1NFE2L2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9227955-B2 | Compound having angiogenesis inhibitory activity, method for preparing same, and pharmaceutical composition comprising same | BORYUNG PHARMACEUTICAL CO., LTD. (KR) | 2016-01-05 | — | — | US | disclosed |
| US-20140256711-A1 | Novel Compound Having Angiogenesis Inhibitory Activity, Method for Preparing Same, and Pharmaceutical Composition Comprising Same | BORYUNG PHARMACEUTICAL CO., LTD. (KR) | 2014-09-11 | — | — | US | disclosed |
| US-20140073631-A1 | ANTIVIRAL AND ANTIMICROBIAL COMPOUNDS | VYMED CORPORATION (US) | 2014-03-13 | — | — | US | disclosed |
| EP-1406619-A4 | ANTIVIRAL AND ANTIMICROBIAL GUANIDINE OR BIGUANIDINE DERIVATIVES | SHETTY B VITHAL (US) | 2005-02-02 | — | — | EP | disclosed |
| US-20040132993-A1 | Antiviral and antimicrobial guanidine or biguanidine derivatives | SHETTY B VITHAL (US) | 2004-07-08 | — | — | US | disclosed |
| EP-1406619-A1 | ANTIVIRAL AND ANTIMICROBIAL GUANIDINE OR BIGUANIDINE DERIVATIVES | Shetty, B. Vithal (US) | 2004-04-14 | — | — | EP | disclosed |
| US-6699989-B1 | HUMAN T-CELL LEUKEMIA/LYMPHOMA VIRUS (HTLV) AND LYMPHADENOPATHY ASSOCIATED VIRUS TREATMENT; AIDS | VYMED CORPORATION | 2004-03-02 | — | — | US | disclosed |
| WO-2002017916-A1 | ANTIVIRAL AND ANTIMICROBIAL GUANIDINE OR BIGUANIDINE DERIVATIVES | SHETTY B VITHAL (US) | 2002-03-07 | — | — | WO | disclosed |
| EP-0302372-B1 | NAPHTHYRIDINE ANTIANAEROBIC COMPOUNDS | ABBOTT LABORATORIES (US) | 1992-12-16 | — | — | EP | disclosed |
| EP-0302372-A1 | Naphthyridine antianaerobic compounds | ABBOTT LABORATORIES (US) | 1989-02-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140256711-A1 | Novel Compound Having Angiogenesis Inhibitory Activity, Method for Preparing Same, and Pharmaceutical Composition Comprising Same | VEGFA, EDF1, FLT1 | KMT2A 4447/4885KEAP1 1541/4885NFE2L2 732/4885 |
| US-20140073631-A1 | ANTIVIRAL AND ANTIMICROBIAL COMPOUNDS | GDA, GMPS, GANC | KMT2A 4199/4885KEAP1 4173/4885NFE2L2 3926/4885 |
| US-20040132993-A1 | Antiviral and antimicrobial guanidine or biguanidine derivatives | GMPS, GDA, GANC | KMT2A 4069/4885KEAP1 4355/4885NFE2L2 4075/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.